- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04119635
Pediatric Penetrating Crohn's Disease (Pediatric B3)
Treatment and Long-term Outcomes of Pediatric Patient With Penetrating Crohn's Disease: the Multicenter Cross-sectional Study
The incidence of Crohn's disease (CD) increased the last few years, especially in children, with 20% percent of CD patients diagnosed during childhood. The CD is a chronic disease without curative treatment, medical or surgical, and evolution is longer in children, avoid iterative digestive resections and their consequences in these patients is a major issue.
The beginning of the disease at pediatric age is considered to be a poor prognostic factor and is considered to be more aggressive than that of adults: more extensive, more active and requiring more immunosuppressive treatments, with a more frequent dependence on corticosteroids and a shorter delay between the beginning of symptoms and the first surgery. After 5 years of evolution, 13 to 50% of patients with early pediatric MC have undergone intestinal resection.
The Paris' classification defined 3 phenotypes or behaviors in pediatric Crohn's disease. Penetrating phenotype (B3) is a heterogeneous group defined by the presence of intra-abdominal perforation, fistulas or abscesses. The B3 phenotype is a risk factor for pejorative evolution in CD with a risk increased of surgical resection.
In the pediatric population, the natural history of patients with penetrating CD is unknown. Most studies focus on CD beginning at pediatric age but with penetrating complications occurring in adulthood or pediatric penetrating CD but with relatively short follow-up. The risk of recurrence of the penetrating disease after a first complication in childhood is unknown, the factors influencing this risk also. And, there is no consensus either concerning optimal B3 management in children, and the practices are variable from specialist to specialist.
After describing the pediatric population with penetrating CD, the aim of this study was to know the incidence of bowel resection for B3 episode. The secondary aims were to describe the immediate management and long-term evolution of these patients and to identify risk factors for adverse evolution.
Study Overview
Status
Conditions
Detailed Description
This study is cross-sectional and is carrying out between 1995 and 2017 in two French tertiary referral centers (Montpellier, Toulouse) and EPIMAD registry which is currently the largest Inflammatory Bowel Disease cohort in world and cover 9.6% of French population (Nord, Pas-de-Calais, Somme, and Seine-Maritime department).
All patients diagnosed with CD who had underwent a B3 complication (intra-abdominal abscess, fistula, perforation, peritonitis, or phlegmon) before the age of 18. Patient having isolated perineal disease, indeterminate colitis or with too much missing data were excluded.
The main endpoint: incidence of intestinal resection performed for B3 complication.
The secondary endpoints:
- description of the pediatric population with B3 complication with:
- demographic data: sex, family history, phenotype of the disease according to the Paris classification, age at diagnosis of B3, period of diagnosis of B3 (before or after 2001), time between the diagnosis of CD and the diagnosis of B3, a history of medical and surgical treatment for CD received before B3.
- clinical data: type of B3 complication, presence of stenosis and its location, clinical symptoms (fever, obstructive symptoms), nutritional status.
- description of the immediate management of these patients, specifying: the place of care, the type of immediate management performed, the drug treatments received in the acute phase, the medical treatments for CD introduced for the B3 episode, the intestinal resections performed for the B3 episode, the realization of a stoma, the radiological drainage of abscesses, the immediate complications of B3.
- description of the long-term evolution of these patients, specifying: the given drug treatments, the clinical recurrence of the CD, the recurrence of B3, the need for intestinal resection during follow-up, the occurrence of other events
- identification of risk factors for pejorative evolution defined by "recurrence of B3" or "intestinal resection" in these patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- UH Montpellier
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- patients diagnosed with CD who had underwent a B3 complication (intra-abdominal abscess, fistula, perforation, peritonitis, or phlegmon)
Exclusion criteria:
- patient having isolated perineal disease, indeterminate colitis or with too much missing data were excluded
- patients refuse the use of medical data will be excluded.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
incidence of intestinal resection performed for B3 complication in pediatric population
Time Frame: through study completion, an average of 10 years
|
|
through study completion, an average of 10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
incidence of recurrence of B3 complication in pediatric population
Time Frame: through study completion, an average of 10 years
|
Incidence of recurrence of B3 complication and specifying :
|
through study completion, an average of 10 years
|
identification of risk factors for pejorative evolution (recurrence of <B3 or intestinal resection) of the pediatric population with B3 complication
Time Frame: through study completion, an average of 10 years.
|
Multivariate analysis with the following data to define parameters associated with "recurrence of B3" or "intestinal resection"
|
through study completion, an average of 10 years.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Laura Kollen, MD, University Hospitals of Montpellier
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RECHMPL19_0366
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Penetrating Crohn's Disease
-
Rhode Island HospitalEnrolling by invitationGastrointestinal Diseases | Colitis | Pediatric Disorder | Pediatric Crohns Disease | Procedural SequelaeUnited States
-
Hôpital Necker-Enfants MaladesInstitut National de la Santé Et de la Recherche Médicale, France; NestléUnknownCrohn's Disease | PediatricFrance
-
Children's Hospital Los AngelesCompleted
-
Hospices Civils de LyonNot yet recruitingCrohn Disease | Pediatric Crohns DiseaseFrance
-
University of North Carolina, Chapel HillUniversity of Amsterdam; Crohn's and Colitis FoundationRecruitingCrohn Disease | Pediatric Crohns DiseaseNetherlands, United States, Canada, Israel
-
Laura MacknerChildren's Hospital Medical Center, CincinnatiRecruitingInflammatory Bowel Diseases | Pediatric Ulcerative Colitis | Pediatric Crohns DiseaseUnited States
-
Klinikum Westbrandenburg GmbHUnknown
-
Azienda Policlinico Umberto ICompletedPediatric | Colon Capsule EndoscopyItaly
-
McMaster UniversityCompletedPediatric Ulcerative Colitis | Pediatric Crohns Disease | Pediatric Inflammatory Bowel DiseasesCanada
-
Vanderbilt University Medical CenterCompleted